Virtu Financial’s 10x Genomics TXG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$3.45M Buy
+38,203
New +$2.23M 0.12% 89
2025
Q4
– Sell
-48,523
Closed -$567K – 2257
2025
Q3
$567K Buy
+48,523
New +$633K 0.03% 508
2023
Q4
– Sell
-9,773
Closed -$403K – 2015
2023
Q3
$403K Buy
+9,773
New +$508K 0.04% 404
2023
Q1
– Sell
-22,815
Closed -$831K – 2115
2022
Q4
$831K Buy
+22,815
New +$746K 0.11% 167
2021
Q4
– Sell
-9,982
Closed -$1.45M – 2186
2021
Q3
$1.45M Sell
9,982
-1,490
-13% -$256K 0.13% 145
2021
Q2
$2.25M Buy
+11,472
New +$2.08M 0.22% 62
2020
Q4
– Sell
-2,173
Closed -$271K – 1807
2020
Q3
$271K Buy
+2,173
New +$228K 0.05% 480

Other funds holding TXG

Virtu Financial's TXG Position: Q3 2026 in Review

Virtu Financial opened a new position in 10x Genomics (TXG) in Q3 2026: 38,203 shares worth $3.45M. The stake represents 0.12% of the portfolio and ranks #89 among its holdings. This is a return to the name: Virtu Financial previously reported a position in TXG as recently as Q3 2025.

Virtu Financial first reported a position in TXG in Q3 2020 and has held it in 7 quarters since. 492 funds tracked by Wall St. Rank hold TXG as of Q3 2026.

  • Virtu Financial held 38,203 shares of 10x Genomics worth $3.45M as of Q3 2026.
  • 10x Genomics was a new Virtu Financial position in Q3 2026.
  • 10x Genomics made up 0.12% of Virtu Financial's portfolio in Q3 2026, its #89 holding.
  • Virtu Financial first reported a position in 10x Genomics in Q3 2020 and has held it in 7 quarters since.
  • 492 funds tracked by Wall St. Rank held 10x Genomics as of Q3 2026.

Based on Virtu Financial's 13F filing for Q3 2026, filed 17 Nov 2026.